6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (269 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placebo controlledpatientsdoublediagnosisprimary
  Phrases that lowered it: disorderevaluate theand safetyto evaluatesafety of
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past trials: 811 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 373 (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 59.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 6.0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past termination rate: 7.4% (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 65 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• AZD7268 Safety and Tolerability Study NCT01020799 · started 2009 · scored riskier than 60% of active trials completed
• AZD6765 Severe Major Depressive Disorder (MDD) IV NCT00781742 · started 2008 · scored riskier than 55% of active trials completed
• A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder NCT01482221 · started 2011 · scored riskier than 68% of active trials completed
• A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder NCT01114698 · started 2011 · scored riskier than 51% of active trials terminated
• A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms NCT01582815 · started 2012 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.